The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2019 | Ghassan Abou-Alfa talks pemigatinib and cabozantinib
Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the initial findings from the FIGHT-202 trial (NCT02924376), a Phase II study of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA). Ghassan goes on to provide an outline of the CELESTIAL trial (NCT01908426) results, and the molecular targets of cabozantinib in hepatocellular carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
